The demo reached the two its Principal endpoints, with semaglutide 2.four mg demonstrating statistically considerable and top-quality improvements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis without having worsening of liver fibrosis in those with MASH in comparison with placebo.onePreserve all a